 | Up a level |
2020
Al-Sawaf, O., Robrecht, S., Fink, A., Ritgen, M., Johansson, P., Staber, P., Jaeger, U., Niemann, C., Pallasch, C., Kreuzer, K., Stilgenbauer, S., Fischer, K., Wendtner, C., Hallek, M. and Eichhorst, B. (2020). The CLL-RT1 trial: A multi-center phase-2 trial to evaluate the efficacy and safety of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for treatment of patients with Richter Transformation. Oncol. Res. Treat., 43 (SUPPL 4). S. 73 - 74. BASEL: KARGER. ISSN 2296-5262
2019
Al-Sawaf, O., Garcia-Borrega, J., Vehreschild, J. J., Thelen, P., Faetkenheuer, G., Shimabukuro-Vornhagen, A., Kochanek, M. and Boell, B. (2019). Pelvic cellulitis caused by Raoultella planticola in a neutropenic patient. J. Infect. Chemother., 25 (4). S. 298 - 302. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1437-7780
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A. -M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Du, K. Le, Fogliatto, L. M., Niemann, C. U., Weinkove, R., Robinson, S., Kipps, T. J., Boettcher, S., Tausch, E., Humerickhouse, R., Eichhorst, B., Wendtner, C. -M., Langerak, A. W., Kreuzer, K. -A., Ritgen, M., Goede, V., Stilgenbauer, S., Mobasher, M. and Hallek, M. (2019). Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N. Engl. J. Med., 380 (23). S. 2225 - 2237. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406
2018
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., Langerbeins, P., von Tresckow, J., Maurer, C., Kutsch, N., Lange, E., Kiehl, M., Fischer, K., Stilgenbauer, S., Wendtner, C-M, Goede, V, Hallek, M. and Eichhorst, B. (2018). Incidence and outcome of Richter transformation in chronic lymphocytic leukaemia (CLL) - A meta-analysis of German CLL Study Group (GCLLSG) trials. Oncol. Res. Treat., 41. S. 166 - 167. BASEL: KARGER. ISSN 2296-5262
Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al-Sawaf, O., Langerbeins, P., Fuerstenau, M., Engelke, A., Fink, A. -M, Fischer, K., Kreuzer, K. -A, Ritgen, M., Boettcher, S., Wendtner, C. -M, Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2018). Comparison of 3 different phase II studies using sequential combinations of targeted agents to treat chronic lymphocytic leukemia. Oncol. Res. Treat., 41. S. 29 - 31. BASEL: KARGER. ISSN 2296-5262
2017
Al-Sawaf, O., Bahlo, J., Fischer, K., Herling, C., Hoechstetter, M., Fink, A., von Tresckow, J., Langerbeins, P., Cramer, P., Stilgenbauer, S., Wendtner, C., Eichhorst, B., Hallek, M. and Goede, V. (2017). CHARACTERISTICS, TREATMENT, AND OUTCOMES OF >= 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. Haematologica, 102. S. 421 - 422. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Al-Sawaf, O., Bahlo, J., Fischer, K., Herling, C., M., Hochstaetter, Fink, A. M., von Tresckow, J., Langerbeins, P., Cramer, P., Stilgenbauer, S., Wendtner, C. M., Eichhorst, B., Hallek, M. and Goede, V. (2017). Characteristics, treatment, and outcomes of >= 80 year old patients with chronic lymphocytic leukemia (CLL) enrolled to prospective trials of the German CLL study group. Oncol. Res. Treat., 40. S. 139 - 140. BASEL: KARGER. ISSN 2296-5262
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., von Tresckow, J., Maurer, C., Bergmann, M., Seiler, T., Lange, E., Kneba, M., Stilgenbauer, S., Doehner, H., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Goede, V., Hallek, M., Eichhorst, B. and Hopfinger, G. (2017). Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia, 31 (10). S. 2251 - 2255. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., von Tresckow, J., Cramer, P., Langerbeins, P., Kutsch, N., Wendtner, C. M., Fischer, K., Eichhorst, B., Goede, V. and Hallek, M. (2017). Mode of progression correlates with further clinical outcome of chronic lymphocytic leukemia (CLL). A meta-analysis by the German CLL study group. Oncol. Res. Treat., 40. S. 138 - 139. BASEL: KARGER. ISSN 2296-5262
Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al-Sawaf, O., Langerbeins, P., Engelke, A., Fink, A. -M., Fischer, K., Tausch, E., Seiler, T., von Weikersthal, Fischer L., Hebart, H., Kreuzer, K. -A., Ritgen, M., Kneba, M., Wendtner, C. -M., Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2017). Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 40. S. 24 - 25. BASEL: KARGER. ISSN 2296-5262
Goede, V., Bahlo, J., Robrecht, S., Al-Sawaf, O., Fink, A. -M., Wendtner, C. -M., Stilgenbauer, S., Fischer, K., Eichhorst, B. and Hallek, M. (2017). CUMULATIVE ILLNESS RATING SCALE PROVIDES PROGNOSTIC INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA: AN ACROSS-TRIAL ANALYSIS BY THE GCLLSG. Haematologica, 102. S. 72 - 73. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
2016
Al-Sawaf, O., Kluth, S., Bahlo, J., Hopfinger, G., Fink, A. M., Cramer, P., Maurer, C., Bergmann, M., Dreyling, M., Lange, E., Kneba, M., Stilgenbauer, S., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 39. S. 212 - 214. BASEL: KARGER. ISSN 2296-5262
Fink, A. M., Maurer, C., Bahlo, J., Kluth, S., Linde, H., Aldaoud, A., Illmer, T., Dengler, J., Klausmann, M., Lathan, B., Al-Sawaf, O., Fischer, K., Wendtner, C. -M, Eichhorst, B. and Hallek, M. (2016). Three years after the start of enrolment: Current data from the prospective CLL-registry of the German CLL Study Group. Oncol. Res. Treat., 39. S. 256 - 257. BASEL: KARGER. ISSN 2296-5262